Premature termination codon read-through in the ABCC6 Gene: Potential treatment for pseudoxanthoma elasticum

Journal of Investigative Dermatology

Volumn 133, Issue 12, 2013, Pages 2672-2677

  Zhou, Yong ^a,b   Jiang, Qiujie ^a   Takahagi, Shunsuke ^a   Shao, Changxia ^a   Uitto, Jouni ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; CYSTEINE; GLYCINE; MESSENGER RNA; MORPHOLINO OLIGONUCLEOTIDE; TRYPTOPHAN;

ABCC6 GENE; AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NONHUMAN; NONSENSE MUTATION; PATHOGENICITY; PHENOTYPE; PREMATURE STOP CODON READ THROUGH; PRIORITY JOURNAL; PSEUDOXANTHOMA ELASTICUM; STOP CODON; ZEBRA FISH;

EID: 84887817786     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.234     Document Type: Article

References (25)

1. Belinsky MG, Kruh GD (1999) MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer 80:1342-9
2. Bordeira-Carrico R, Pego AP, Santos M et al. (2012) Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 18:667-78
3. Du M, Liu X, Welch EM et al. (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 105:2064-9
4. Finger RP, Charbel Issa P, Ladewig MS et al. (2009) Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol 54:272-85
5. Finkel RS (2010) Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 25:1158-64
6. Georgalas I, Tservakis I, Papaconstaninou D et al. (2011) Pseudoxanthoma elasticum, ocular manifestations, complications and treatment. Clin Exp Optom 94:169-80
7. Gorgels TG, Hu X, Scheffer GL et al. (2005) Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet 14:1763-73
8. Hirawat S, Welch EM, Elfring GL et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47:430-44
9. Ho G, Reichardt J, Christodoulou J (2013) In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria. J Inherit Metab Dis. e-pub ahead of print 27 March 2013
10. Howard MT, Shirts BH, Petros LM et al. (2000) Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 48:164-9
11. Kayali R, Ku JM, Khitrov G et al. (2012) Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet 21:4007-20
12. Klement JF, Matsuzaki Y, Jiang QJ et al. (2005) Targeted ablation of the Abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol 25:8299-310
13. Li Q, Frank M, Thisse CI et al. (2011) Zebrafish: a model system to study heritable skin diseases. J Invest Dermatol 131:565-71
14. Li Q, Sadowski S, Frank M et al. (2010) The abcc6a gene expression is required for normal zebrafish development. J Invest Dermatol 130:2561-8
15. Neldner KH (1988) Pseudoxanthoma elasticum. Clin Dermatol 6:1-159
16. Nilsson M, Ryden-Aulin M (2003) Glutamine is incorporated at the nonsense codons UAG and UAA in a suppressor-free Escherichia coli strain. Biochim Biophys Acta 1627:1-6
17. Peltz SW, Morsy M, Welch EM et al. (2013) Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64:407-25
18. Rowe SM, Clancy JP (2009) Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 23:165-74
19. Sanchez-Alcudia R, Perez B, Ugarte M et al. (2012) Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia. Hum Mutat 33:973-80
20. Tan L, Narayan SB, Chen J et al. (2011) PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis 34:443-7
21. Uitto J (2012) Rare heritable skin diseases: targets for regenerative medicine. J Invest Dermatol 132:2485-8
22. Uitto J, Váradi A, Bercovitch L et al. (2013) Pseudoxanthoma elasticum: Progress in research toward treatment: Summary of the 2012 PXE International Research Meeting. J Invest Dermatol 133:1444-9
23. Uitto J, Li Q, Jiang Q (2010) Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Invest Dermatol 130:661-70
24. Welch EM, Barton ER, Zhuo J et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91
25. Wilschanski M, Miller LL, Shoseyov D et al. (2011) Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38:59-69